The clinical use of cetirizine in the treatment of allergic rhinitis

Pharmacology

Volumn 92, Issue 1-2, 2013, Pages 14-25

  Zhang, Luo ^a   Cheng, Lei ^b   Hong, Jianguo ^c  

^a CAPITAL MEDICAL UNIVERSITY   (China)

^b NANJING MEDICAL UNIVERSITY   (China)

^c SHANGHAI JIAO TONG UNIVERSITY   (China)

Author keywords

Allergic rhinitis; Benchmark; Cetirizine; Efficacy; H1< inf> antihistamines; Pharmacodynamics; Pharmacokinetics; Quality of life; Safety; Somnolence

Indexed keywords

ANTIHISTAMINIC AGENT; CETIRIZINE;

ALLERGIC RHINITIS; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL (TOPIC); DRUG BINDING; DRUG EFFICACY; DRUG SAFETY; HUMAN; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; VOLUME OF DISTRIBUTION;

ANTI-ALLERGIC AGENTS; CETIRIZINE; HISTAMINE H1 ANTAGONISTS, NON-SEDATING; HUMANS; RHINITIS, ALLERGIC, PERENNIAL; RHINITIS, ALLERGIC, SEASONAL;

EID: 84880181476     PISSN: 00317012     EISSN: 14230313     Source Type: Journal    
DOI: 10.1159/000351843     Document Type: Review

References (92)

1. Schatz M: A survey of the burden of allergic rhinitis in the USA. Allergy 2007; 62(suppl 85):9-16.
2. Canonica GW, Bousquet J, Mullol J, et al: A survey of the burden of allergic rhinitis in Europe. Allergy 2007; 62(suppl 85):17-25.
3. Schoenwetter WF, Dupclay L, Appajosyula S, et al: Economic impact and quality of life burden of allergic rhinitis. Curr Med Res Opin 2004; 20: 305-317.
4. Meltzer EO, Nathan R, Derebery J, et al: Sleep, quality of life, and productivity impact of nasal symptoms in the United States: findings from the Burden of Rhinitis in America survey. Allergy Asthma Proc 2009; 30: 244-254.
5. Nathan RA: The burden of allergic rhinitis. Allergy Asthma Proc 2007; 28: 3-9.
6. Blaiss MS: Pediatric allergic rhinitis: physical and mental complications. Allergy Asthma Proc 2007; 29: 1-6.
7. Meltzer EO, Blaiss MS, Derebery MJ, et al: Burden of allergic rhinitis: results from the Pediatric Allergies in America survey. J Allergy Clin Immunol 2009; 124(suppl): S43-S70.
8. Katelaris CH, Lee BW, Potter PC, et al: Prevalence and diversity of allergic rhinitis in regions of the world beyond Europe and North America. Clin Exp Allergy 2012; 42: 186-207.
9. Zhang L, Han D, Huang D, Wu Y, Dong Z, et al: Prevalence of self-reported allergic rhinitis in eleven major cities in China. Int Arch Allergy Immunol 2009; 149: 47-57.
10. Mösges R, Klimek L: Today's allergic rhinitis patients are different: new factors that may play a role. Allergy 2007: 62: 969-975.
11. Barnes C, Dinakar C, Reddy M, Portnoy J: Frequency of fungi in homes of pediatric allergy patients. Allergy Clin Immunol Int J World Allergy Org 2006; 18: 197-202.
12. Bousquet J, Khaltaev N, Cruz AA, et al: Allergic Rhinitis and Its Impact on Asthma (ARIA) 2008 update [in collaboration with the World Health Organization, GA(2)LEN and Aller-Gen]. Allergy 2008; 63(suppl 86):8-160.
13. Wallace DV, Dykewicz MS, Bernstein DI, et al: The diagnosis and management of rhinitis: an updated practice parameter. J Allergy Clin Immunol 2008; 122(suppl):S1-S84.
14. Scadding GK, Durham SR, Mirakian R, et al: BSACI guidelines for the management of allergic and non-allergic rhinitis. Clin Exp Allergy 2008; 38: 19-42.
15. Emanuel MB: Histamine and antiallergic antihistamines: a history of their discoveries. Clin Exp Allergy 1999; 29(suppl 3):1-11.
16. Simons FE, Simons KJ: Histamine and H 1 antihistamines: celebrating a century of progress. J Allergy Clin Immunol 2011; 128: 1139-1150.
17. Church MK, Maurer M, Simons FE, et al: Risk of first-generation H 1 antihistamines: a GA(2) LEN position paper. Allergy 2010; 65: 459-466.
18. Schad CA, Skoner DP: Antihistamines in the pediatric population: achieving optimal outcomes when treating seasonal allergic rhinitis and chronic urticaria. Allergy Asthma Proc 2008; 29: 7-13.
19. Taglialatela M, Castaldo P, Pannaccione A, et al: Cardiac ion channels and antihistamines: possible mechanisms of cardiotoxicity. Clin Exp Allergy 1999; 29(suppl 3):182-189.
20. Tillement J-P, Testa B, Bre F: Compared pharmacological characteristics in humans of racemic cetirizine and levocetirizine, two histamine H 1 -receptor antagonists. Biochem Pharmacol 2003; 66: 1123-1126.
21. Pagliara A, Testa B, Carrupt PA, et al: Molecular properties and pharmacokinetic behavior of cetirizine, a zwitterionic H 1 -receptor antagonist. J Med Chem 1998; 41: 853-863.
22. Tillement JP: The advantages for an H 1 antihistamine of a low volume of distribution. Allergy 2000; 55(suppl 60):17-21.
23. Wood SG, John BA, Chasseaud LF, et al: The metabolism and pharmacokinetics of 14 C-cetirizine in humans. Ann Allergy 1987; 59: 31-34.
24. Greisner WA 3rd: Onset of action for the relief of allergic rhinitis symptoms with secondgeneration antihistamines. Allergy Asthma Proc 2004; 25: 81-83.
25. Horsmans Y, Desager JP, Hulhoven R, et al: Single-dose pharmacokinetics of cetirizine in patients with chronic liver disease. J Clin Pharmacol 1993; 33: 929-932.
26. Boobis A, Watelet JB, Whomsley R, et al: Drug interactions. Drug Metab Rev 2009; 41: 486-527.
27. Lefebvre RA, Rosseel MT, Bernheim J: Single dose pharmacokinetics of cetirizine in young and elderly volunteers. Int J Clin Pharmacol Res 1988; 8: 463-470.
28. Gillard M, Christophe B, Wels B, et al: H 1 antagonists: receptor affinity versus selectivity. Inflamm Res 2003; 52(suppl 1):S49-S50.
29. Fadel R, Herpin-Richard N, Rihoux JP, et al: Inhibitory effect of cetirizine 2 HCl on eosinophil migration in vivo. Clin Allergy 1987; 17: 373-379.
30. Watson WT, Simons KJ, Chen XY, et al: Cetirizine: a pharmacokinetic and pharmacodynamic evaluation in children with seasonal allergic rhinitis. J Allergy Clin Immunol 1989; 84: 457-464.
31. Ciprandi G, Tosca M, Ricca V, et al: Cetirizine treatment of rhinitis in children with pollen allergy: evidence of its antiallergic activity. Clin Exp Allergy 1997; 27: 1160-1166.
32. Ciprandi G, Tosca MA, Milanese M, et al: Cetirizine reduces cytokines and inflammatory cells in children with perennial allergic rhinitis. Eur Ann Allergy Clin Immunol 2004; 36: 237-240.
33. Fasce L, Ciprandi G, Pronzato C, et al: Cetirizine reduces ICAM-I on epithelial cells during nasal minimal persistent inflammation in asymptomatic children with mite-allergic asthma. Int Arch Allergy Immunol 1996; 109: 272-276.
34. Ciprandi G, Passalacqua G, Mincarini M, et al: Continuous versus on demand treatment with cetirizine for allergic rhinitis. Ann Allergy Asthma Immunol 1997; 79: 507-511.
35. Lauriello M, Muzi P, Di Rienzo L, et al: A twoyear course of specific immunotherapy or of continuous antihistamine treatment reverses eosinophilic inflammation in severe persistent allergic rhinitis. Acta Otorhinolaryngol Ital 2005; 25: 284-291.
36. Shirasaki H, Watanabe K, Kanaizumi E, et al: Effects of cetirizine on substance P release in patients with perennial allergic rhinitis. Ann Otol Rhinol Laryngol 2004; 113: 941-945.
37. Grant JA, Danielson L, Rihoux JP, et al: A double-blind, single-dose, crossover comparison of cetirizine, ebastine, epinastine, fexofenadine, terfenadine, and loratadine versus placebo: suppression of histamine-induced wheal and flare response for 24 h in healthy male subjects. Allergy 1999; 54: 700-707.
38. Curran MP, Scott LJ, Perry CM: Cetirizine: a review of its use in allergic disorders. Drugs 2004; 64: 523-561.
39. Takahashi H, Ishida-Yamamoto A, Iizuka H: Effects of bepotastine, cetirizine, fexofenadine, and olopatadine on histamine-induced wheal-and flare response, sedation, and psychomotor performance. Clin Exp Dermatol 2004; 29: 526-532.
40. Church MK: Comparative inhibition by bilastine and cetirizine of histamine-induced wheal and flare responses in humans. Inflamm Res 2011; 60: 1107-1112.
41. Purohit A, Melac M, Pauli G, et al: Comparative activity of cetirizine and desloratadine on histamine-induced wheal-and-flare responses during 24 h. Ann Allergy Asthma Immunol 2004; 92: 635-640.
42. Devalia JL, De Vos C, Hanotte F, et al: A randomized, double-blind, crossover comparison among cetirizine, levocetirizine, and UCB 28557 on histamine-induced cutaneous responses in healthy adult volunteers. Allergy 2001; 56: 50-57.
43. Panayotopoulos SM, Panayotopoulou ES: Efficacy of cetirizine in the treatment of seasonal allergic rhinoconjunctivitis. Ann Allergy 1990; 65: 146-168.
44. Falliers CJ, Brandon ML, Buchman E, et al: Double-blind comparison of cetirizine and placebo in the treatment of seasonal rhinitis. Ann Allergy 1991; 66: 257-262.
45. Allegra L, Paupe J, Wieseman HG, et al: Cetirizine for seasonal allergic rhinitis in children aged 2-6 years. A double-blind comparison with placebo. Pediatr Allergy Immunol 1993; 4: 157-161.
46. Masi M, Candiani R, van de Venne H: A placebo-controlled trial of cetirizine in seasonal allergic rhino-conjunctivitis in children aged 6 to 12 years. Pediatr Allergy Immunol 1993; 4(suppl 4):47-52.
47. Pearlman DS, Lumry WR, Winder JA, et al: Once-daily cetirizine effective in the treatment of seasonal allergic rhinitis in children aged 6 to 11 years: a randomized, doubleblind, placebo-controlled study. Clin Pediatr (Phila) 1997; 36: 209-215.
48. Gillman SA, Blatter M, Condemi JJ, et al: The health-related quality of life effects of oncedaily cetirizine HCl syrup in children with seasonal allergic rhinitis. Clin Pediatr (Phila) 2002; 41: 687-696.
49. Murray JJ, Nathan RA, Bronsky EA, et al: Comprehensive evaluation of cetirizine in the management of seasonal allergic rhinitis: impact on symptoms, quality of life, productivity, and activity impairment. Allergy Asthma Proc 2002; 23: 391-398.
50. Noonan MJ, Raphael GD, Nayak A, et al: The health-related quality of life effects of oncedaily cetirizine HCl in patients with seasonal allergic rhinitis: a randomized double-blind, placebo-controlled trial. Clin Exp Allergy 2003; 33: 351-358.
51. Mansmann HC Jr, Altman RA, Berman BA, et al: Efficacy and safety of cetirizine therapy in perennial allergic rhinitis. Ann Allergy 1992; 68: 348-353.
52. Jobst S, van den Wijngaart W, Schubert A, et al: Assessment of the efficacy and safety of three dose levels of cetirizine given once daily in children with perennial allergic rhinitis. Allergy 1994; 49: 598-604.
53. Bousquet J, Duchateau J, Pignat JC, et al: Improvement of quality of life by treatment with cetirizine in patients with perennial allergic rhinitis as determined by a French version of the SF-36 questionnaire. J Allergy Clin Immunol 1996; 98: 309-316.
54. Burtin B, Duchateau J, Pignat JC, et al: Further improvement of quality of life by cetirizine in perennial allergic rhinitis as a function of treatment duration. J Investig Allergol Clin Immunol 2000; 10: 66-70.
55. Berkowitz RB, Dockhom R, Lockey R, et al: Comparison of efficacy, safety, and skin test inhibition of cetirizine and astemizole. Ann Allergy Asthma Immunol 1996; 76: 363-368.
56. Lockey RF, Widlitz MD, Mitchell DQ, et al: Comparative study of cetirizine and terfenadine versus placebo in the symptomatic management of seasonal allergic rhinitis. Ann Allergy Asthma Immunol 1996; 76: 448-454.
57. Gehanno P, Bremard-Oury C, Zeisser P: Comparison of ebastine to cetirizine in seasonal allergic rhinitis in adults. Ann Allergy Asthma Immunol 1996; 76: 507-512.
58. Meltzer EO, Weiler JM, Widlitz MD: Comparative outdoor study of the efficacy, onset and duration of action, and safety of cetirizine, loratadine, and placebo for seasonal allergic rhinitis. J Allergy Clin Immunol 1996; 97: 617-626.
59. Day JH, Briscoe MP, Clark RH, et al: Onset of action and efficacy of terfenadine, astemizole, cetirizine, and loratadine for the relief of symptoms of allergic rhinitis. Ann Allergy Asthma Immunol 1997; 79: 163-172.
60. Day JH, Briscoe M, Widlitz MD: Cetirizine, loratadine, or placebo in subjects with seasonal allergic rhinitis: effects after controlled ragweed pollen challenge in an environmental exposure unit. J Allergy Clin Immunol 1998; 101: 638-645.
61. Day JH, Briscoe M, Rafeiro E, et al: Comparative onset of action and symptom relief with cetirizine, loratadine, or placebo in an environmental exposure unit in subjects with seasonal allergic rhinitis: confirmation of a test system. Ann Allergy Asthma Immunol 2001; 87: 474-481.
62. Day JH, Briscoe MP, Rafeiro E, et al: Randomized double-blind comparison of cetirizine and fexofenadine after pollen challenge in the environmental exposure unit: duration of effect in subjects with seasonal allergic rhinitis. Allergy Asthma Proc 2004; 25: 59-68.
63. Day JH, Briscoe MP, Rafeiro E, et al: Comparative efficacy of cetirizine and fexofenadine for seasonal allergic rhinitis, 5-12 h postdose, in the environmental exposure unit. Allergy Asthma Proc 2005; 26: 275-282.
64. Horak F, Stübner P, Zieglmayer R, et al: Controlled comparison of the efficacy and safety of cetirizine 10 mg o.d. and fexofenadine 120 mg o.d. in reducing symptoms of seasonal allergic rhinitis. Int Arch Allergy Immunol 2001; 125: 73-79.
65. Howarth PH, Stem MA, Roi L, et al: Doubleblind, placebo controlled study comparing the efficacy and safety of fexofenadine hydrochloride (120 and 180 mg once daily) and cetirizine in seasonal allergic rhinitis. J Allergy Clin Immunol 1999; 104: 927-933.
66. Hampel F, Ratner P, Mansfield L, et al: Fexofenadine hydrochloride, 180 mg, exhibits equivalent efficacy to cetirizine, 10 mg, with less drowsiness in patients with moderate-tosevere seasonal allergic rhinitis. Ann Allergy Asthma Immunol 2003; 91: 354-361.
67. Sabbah A, Daele J, Wade AG, et al: Comparison of the efficacy, safety, and onset of action of mizolastine, cetirizine, and placebo in the management of seasonal allergic rhinoconjunctivitis. MIZOCET Study Group. Ann Allergy Asthma Immunol 1999; 83: 319-325.
68. Horak F, Stübner P, Zieglmayer R, et al: Clinical study of the therapeutic efficacy and safety of emedastine difumarate versus cetirizine in the treatment of seasonal allergic rhinitis. Arzneimittelforschung 2004; 54: 666-672.
69. Martnez-Ccera C, De Molina M, Mart-Guadao E, et al: Rupatadine 10 mg and cetirizine 10 mg in seasonal allergic rhinitis: a randomised, double-blind parallel study. J Investig Allergol Clin Immunol 2005; 15: 22-29.
70. Kuna P, Bachert C, Nowacki Z, et al: Efficacy and safety of bilastine 20 mg compared with cetirizine 10 mg and placebo for the symptomatic treatment of seasonal allergic rhinitis: a randomized, double-blind, parallelgroup study. Clin Exp Allergy 2009; 39: 1338-1347.
71. Berger W, Hampel F Jr, Bernstein J, et al: Impact of azelastine nasal spray on symptoms and quality of life compared with cetirizine oral tablets in patients with seasonal allergic rhinitis. Ann Allergy Asthma Immunol 2006; 97: 375-381.
72. Corren J, Storms W, Bernstein J, et al: Effectiveness of azelastine nasal spray compared with oral cetirizine in patients with seasonal allergic rhinitis. Clin Ther 2005; 27: 543-553.
73. Sienra-Monge JJ, Gazca-Aguilar A, Del Rio-Navarro B: Double-blind comparison of cetirizine and loratadine in children ages 2 to 6 years with perennial allergic rhinitis. Am J Ther 1999; 6: 149-155.
74. Lai DS, Lue KH, Hsieh JC, et al: The comparison of the efficacy and safety of cetirizine, oxatomide, ketotifen, and a placebo for the treatment of childhood perennial allergic rhinitis. Ann Allergy Asthma Immunol 2002; 89: 589-598.
75. Renton R, Fidler C, Rosenberg R: Multicenter, crossover study of the efficacy and tolerability of terfenadine, 120 mg, versus cetinzine, 10 mg, in perennial allergic rhinitis. Ann Allergy 1991; 67: 416-420.
76. Murris-Espin M, Melac M, Charpentier JC, et al: Comparison of efficacy and safety of cetirizine and ebastine in patients with perennial allergic rhinitis. Ann Allergy Asthma Immunol 1998; 80: 399-403.
77. Nunes C, Ladeira S: Double-blind study of cetirizine and loratadine versus placebo in patients with allergic rhinitis. J Investig Allergol Clin Immunol 2000; 10: 20-23.
78. Fantin S, Maspero J, Bisbal C, et al: A 12-week placebo-controlled study of rupatadine 10 mg once daily compared with cetirizine 10 mg once daily, in the treatment of persistent allergic rhinitis. Allergy 2008; 63: 924-931.
79. Marmouz F, Giralt J, Izquierdo I: Morning and evening efficacy evaluation of rupatadine (10 and 20 mg), compared with cetirizine 10 mg in perennial allergic rhinitis: a randomized, double-blind, placebo-controlled trial. J Asthma Allergy 2011; 4: 27-35.
80. Sastre J, Mullol J, Valero A, et al: Efficacy and safety of bilastine 20 mg compared with cetirizine 10 mg and placebo in the treatment of perennial allergic rhinitis. Curr Med Res Opin 2012; 28: 121-130.
81. Rinne J, Simola M, Malmberg H, et al: Early treatment of perennial rhinitis with budesonide or cetirizine and its effect on long-term outcome. J Allergy Clin Immunol 2002; 109: 426-432.
82. Chen ST, Lu KH, Sun HL, Chang WT, Lue KH, Chou MC: Randomized placebo-controlled trial comparing montelukast and cetirizine for treating perennial allergic rhinitis in children aged 2-6 yr. Pediatr Allergy Immunol 2006; 17: 49-54.
83. Philip G, Williams-Herman D, Patel P, Weinstein SF, Alon A, Gilles L, Tozzi CA, Dass SB, Reiss TF: Efficacy of montelukast for treating perennial allergic rhinitis. Allergy Asthma Proc 2007; 28: 296-304.
84. Daley-Yates P, Ambery C, Sweeney L, et al: The efficacy and tolerability of two novel H 1 / H 3 receptor antagonists in seasonal allergic rhinitis. Int Arch Allergy Immunol 2012; 158: 84-98.
85. Yap YG, Camm AJ: Potential cardiac toxicity of H 1 -antihistamines.Clin Allergy Immunol 2002; 17: 389-419.
86. Davie C, Pierre-Valentin J, Pollard C, et al: Comparative pharmacology of guinea pig cardiac myocyte and cloned hERG (I(Kr)) channel. J Cardiovasc Electrophysiol 2004; 15: 1302-1309.
87. Yanai K, Rogala B, Chugh K, et al: Safety considerations in the management of allergic diseases: focus on antihistamines. Curr Med Res Opin 2012; 28: 623-642.
88. Theunissen EL, Vermeeren A, Ramaekers JG: Repeated-dose effects of mequitazine, cetirizine and dexchlorpheniramine on driving and psychomotor performance. Br J Clin Pharmacol 2006; 61: 79-86.
89. Simons FE: Prospective, long-term safety evaluation of the H 1 -receptor antagonist cetirizine in very young children with atopic dermatitis. ETAC Study Group. Early Treatment of the Atopic Child. J Allergy Clin Immunol 1999; 104: 433-440.
90. Golightly LK, Greos LS: Second-generation antihistamines: actions and efficacy in the management of allergic disorders. Drugs 2005; 65: 341-384.
91. Gillman S, Gillard M, Strolin Benedetti M: The concept of receptor occupancy to predict clinical efficacy: a comparison of second generation H 1 antihistamines. Allergy Asthma Proc 2009; 30: 366-376.
92. Chu NN, Chen WL, Xu HR, Li XN: Pharmacokinetics of orally administered single-and multiple-dose olopatadine in healthy Chinese subjects: an open-label study. Clin Drug Investig 2009; 29: 451-457.